Capecitabine News and Research

RSS
CTCA at Western announces launch of Phase II NivoPlus clinical trial

CTCA at Western announces launch of Phase II NivoPlus clinical trial

FDA approves Vistogard (uridine triacetate) for emergency treatment of chemotherapy overdose

FDA approves Vistogard (uridine triacetate) for emergency treatment of chemotherapy overdose

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Drug combination lengthens lives of metastatic colorectal cancer patients

Drug combination lengthens lives of metastatic colorectal cancer patients

Eribulin therapy effective in women with metastatic breast cancer

Eribulin therapy effective in women with metastatic breast cancer

Eribulin drug has minor added benefit in one patient group, indication of lesser benefit in others

Eribulin drug has minor added benefit in one patient group, indication of lesser benefit in others

NCCN ORP awards four research grants to advance development of nintedanib

NCCN ORP awards four research grants to advance development of nintedanib

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Teva launches generic Xeloda Tablets in the U.S.

Teva launches generic Xeloda Tablets in the U.S.

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

First generic version of Xeloda gets FDA approval for breast and colorectal cancers

First generic version of Xeloda gets FDA approval for breast and colorectal cancers

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Adding chemotherapy after surgery for patients with advanced gastric cancer can reduce mortality risk

Adding chemotherapy after surgery for patients with advanced gastric cancer can reduce mortality risk

Eribulin shows increased benefit among women sharing certain traits

Eribulin shows increased benefit among women sharing certain traits

Report: 83% of cancer doctors face oncology drug shortages

Report: 83% of cancer doctors face oncology drug shortages

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer